Targets › TPBG
3 programs from 3 companies in 3 trials: 3 Phase 1; Oncology; next expected readout Mar 2027.
May function as an inhibitor of Wnt/beta-catenin signaling by indirectly interacting with LRP6 and blocking Wnt3a-dependent LRP6 internalization. (UniProt, Q13641)
Open in Phaseline: the race on TPBG, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| NeoTX Therapeutics | Naptumomab estafenatox Trophoblast glycoprotein other | TPBG | Phase 1 | ER+ Breast Cancer | Mar 2027 |
| Qilu Pharmaceutical | QLS5212 anti-trophoblast glycoprotein (TPBG) antibody-drug conjugate | TPBG | Phase 1 | Solid Tumor Cancer | Nov 2027 |
| Salubris Biotherapeutics | JK06 Biparatopic anti-5T4 antibody | TPBG | Phase 1 | Solid Tumor | Apr 2028 |
Solid Tumor (1) ER+ Breast Cancer (1) Solid Tumor Cancer (1)
small molecule (2), antibody (1)
Salubris Biotherapeutics (1) NeoTX Therapeutics (1) Qilu Pharmaceutical (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.